CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them

被引：11

作者：

Vanhooren, Jolien ^{[1
,2
,3
]}

Dobbelaere, Rani ^{[1
]}

Derpoorter, Charlotte ^{[1
,2
,3
]}

Deneweth, Larissa ^{[2
,3
]}

Van Camp, Laurens ^{[1
,2
,3
]}

Uyttebroeck, Anne ^{[4
]}

De Moerloose, Barbara ^{[1
,2
,3
]}

Lammens, Tim ^{[1
,2
,3
]}

机构：

[1] Univ Ghent, Dept Internal Med & Pediat, Ghent, Belgium

[2] Ghent Univ Hosp, Dept Pediat Hematol Oncol & Stem Cell Transplantat, Ghent, Belgium

[3] Canc Res Inst Ghent, Ghent, Belgium

[4] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Pediat Hematol & Oncol, Dept Oncol, Leuven, Belgium

来源：

HEMASPHERE | 2023年 / 7卷 / 09期

关键词：

CHIMERIC ANTIGEN RECEPTOR; CELL IMMUNOTHERAPY; THERAPY; EXPRESSION; RELEASE; AML; IDENTIFICATION; CYTOTOXICITY; PROGNOSIS; BLASTS;

D O I：

10.1097/HS9.0000000000000937

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Conventional therapies for acute myeloid leukemia (AML) are characterized by high rates of relapse, severe toxicities, and poor overall survival rates. Thus, the development of new therapeutic strategies is crucial for improving the survival and quality of life of AML patients. CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy has been extremely successful in the treatment of B-cell acute lymphoid leukemia and several mature B-cell lymphomas. However, the use of CAR T-cell therapy for AML is currently prevented due to the lack of a myeloid equivalent to CD19, as currently known cell surface targets on leukemic blasts are also expressed on healthy hematopoietic stem and progenitor cells as well as their progeny. In addition, the immunosuppressive tumor microenvironment has a dampening effect on the antitumor activity of CAR-T cells. Here, we review the therapeutic challenges limiting the use of CAR T-cell therapy for AML and discuss promising novel strategies to overcome them.

引用

页数：10

共 94 条

[1] To go or not to go? Biological logic gating engineered T cells [J].

Abbott, Rebecca C. ;

Hughes-Parry, Hannah E. ;

Jenkins, Misty R. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)

[2] NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML [J].

Adamia, Sophia ;

Bar-Natan, Michal ;

Haibe-Kains, Benjamin ;

Pilarski, Patrick M. ;

Bach, Christian ;

Pevzner, Samuel ;

Calimeri, Teresa ;

Avet-Loiseau, Herve ;

Lode, Laurence ;

Verselis, Sigitas ;

Fox, Edward A. ;

Galinsky, Ilene ;

Mathews, Steven ;

Dagogo-Jack, Ibiayi ;

Wadleigh, Martha ;

Steensma, David P. ;

Motyckova, Gabriela ;

Deangelo, Daniel J. ;

Quackenbush, John ;

Tenen, Daniel G. ;

Stone, Richard M. ;

Griffin, James D. .

BLOOD, 2014, 123 (18) :2816-2825

[3] DRUG-REGULATABLE ENGINEERED T CELLS ELIMINATE CD33+AND CD33DE2+AML [J].

Appelbaum, Jacob ;

Leung, Wai-Hang ;

Martin, Unja ;

Oda, Kaori ;

Tampella, Giacomo ;

Xia, Dong ;

Zhang, Joy ;

Krostag, Anne-Rachael ;

Logan, Rachael ;

Evandy, Claudya ;

Vong, Quennie ;

Jones, Kyle ;

Timmer, John ;

Eckelman, Brendan ;

Rottman, Jim ;

Montt, Danielle ;

Peguero, Bryan ;

Pogson, Mark ;

Astrakhan, Alexander ;

Jarjour, Jordan ;

Gustafson, Joshua ;

Jensen, Michael .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 :A63-A63

[4] Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy [J].

Atilla, Pinar Ataca ;

McKenna, Mary K. ;

Watanabe, Norihiro ;

Mamonkin, Maksim ;

Brenner, Malcolm K. ;

Atilla, Erden .

CYTOTHERAPY, 2022, 24 (03) :282-290

[5] Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy [J].

Beavis, Paul A. ;

Henderson, Melissa A. ;

Giuffrida, Lauren ;

Mills, Jane K. ;

Sek, Kevin ;

Cross, Ryan S. ;

Davenport, Alexander J. ;

John, Liza B. ;

Mardiana, Sherly ;

Slaney, Clare Y. ;

Johnstone, Ricky W. ;

Trapani, Joseph A. ;

Stagg, John ;

Loi, Sherene ;

Kats, Lev ;

Gyorki, David ;

Kershaw, Michael H. ;

Darcy, Phillip K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (03) :929-941

[6] Neoantigens in Hematologic Malignancies [J].

Biernacki, Melinda A. ;

Bleakley, Marie .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[7] Development of CAR T Cell Therapy in Children-A Comprehensive Overview [J].

Boettcher, Michael ;

Joechner, Alexander ;

Li, Ziduo ;

Yang, Sile Fiona ;

Schlegel, Patrick .

JOURNAL OF CLINICAL MEDICINE, 2022, 11 (08)

[8] Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies [J].

Borot, Florence ;

Wang, Hui ;

Ma, Yan ;

Jafarov, Toghrul ;

Raza, Azra ;

Ali, Abdullah Mahmood ;

Mukherjee, Siddhartha .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (24) :11978-11987

[9] Chimeric Fv-ξ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells [J].

Brocker, T .

BLOOD, 2000, 96 (05) :1999-2001

[10] Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma [J].

Caimi, Paolo F. ;

Pacheco Sanchez, Gabriela ;

Sharma, Ashish ;

Otegbeye, Folashade ;

Ahmed, Nausheen ;

Rojas, Patricio ;

Patel, Seema ;

Kleinsorge Block, Sarah ;

Schiavone, Jennifer ;

Zamborsky, Kayla ;

Boughan, Kirsten ;

Hillian, Antoinette ;

Reese-Koc, Jane ;

Maschan, Mikhail ;

Dropulic, Boro ;

Sekaly, Rafick-Pierre ;

De Lima, Marcos .

FRONTIERS IN IMMUNOLOGY, 2021, 12

← 1 2 3 4 5 6 7 8 9 10 →